Unicycive Therapeutics (UNCY) Corporate presentation summary

Corporate overview and strategy

• Focused on novel treatments for kidney disease, with a diversified portfolio and strong IP protection extending potentially to 2035.

• Lead asset OLC targets hyperphosphatemia in chronic kidney disease patients on dialysis; UNI-494 is in development for acute kidney injury.

• Management team has a proven track record in developing and commercializing kidney drugs.

• Cash runway extends into 2027, with $61.4 million in cash and $102 million in potential warrant funding.

Market opportunity and unmet need

• Hyperphosphatemia represents a US market opportunity exceeding $1 billion, with over 550,000 dialysis patients and 80% receiving phosphate binders.

• Despite six approved therapies, 75% of patients fail to achieve target serum phosphorus levels, mainly due to high pill burden and poor adherence.

• Lower pill burden is the greatest unmet need, as dialysis patients take a median of 19 pills daily, with 49% from phosphate binders.

OLC product profile and clinical data

• OLC uses proprietary nanoparticle technology for high potency, low pill burden, and palatable formulation, swallowed whole with water.

• Pivotal study showed 91% of patients achieved phosphate control, with 69% reaching targets at ≤1500 mg/day.

• Safety profile compares favorably to other phosphate binders, with most adverse events mild to moderate and low discontinuation rates.

• 79% of patients preferred OLC over prior therapy, citing ease of use and satisfaction.